Soleno Therapeutics SLNO 深 沪
已收盘 12-19 16:00:00 美东时间
47.82
-0.560
-1.16%
华盛通- 最 高55.4676
- 今 开48.59
- 成交量 111.74万股
- 最 低 45.79
- 昨 收 48.38
- 总市值 57.38亿
- 52周最高 90.3199
- 市盈率 静 --
- 换手率 0.93%
- 52周最低 41.58
- 委 比 51.62%
- 总股本 1.20亿
- 历史最高 90.3199
- 量 比 0.95
- 振 幅 20.00%
- 历史最低 0.134
- 每 手 1
- 风险率 14.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Rhythm Pharma rises after early Prader-Willi trial data show reduced hunger and BMI, supporting plans for a Phase 3 study of setmelanotide.
12-12 02:17
Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future
Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.
11-11 23:22
Soleno Therapeutics Announces $100M Accelerated Share Repurchase Plan
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share
11-11 20:01
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
Soleno Therapeutics的Diazoxide Choline Prolonged-Release Tablets (DCCR)获得EMA验证，寻求在欧盟批准用于治疗Prader-Willi综合征引起的过度进食。公司估计欧盟地区有约9,500名患者，并已获得孤儿药指定，有望获得10年市场独占权。该药物已在美国获得批准，并命名为VYKAT XR。
05-22 21:32
凯雷Q4重仓押注StandardAero 建仓中国自动驾驶公司文远知行、小马智行
根据美国证券交易委员会(SEC)披露，全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2024年12月31日的第四季度持仓报告(13F)。 据统计，凯雷第四季度持仓总市值为41.5亿美元，上一季度总市值为9.5亿美元，环比大幅增长近40%。凯雷在第四季度的美股投资组合中新增6只个股，增持了2只个股，减持了5只个股，清仓5只个股。其中前十大持仓标的占总市值的99.16%。 在前十大重仓股中，StandardAero(SARO.US)位列第一，持仓约667.6万股，持仓市值约38.67亿美元，占投资组合比例高达91.09%，为凯雷本季度新增标的。 据了解，Standard...
02-14 17:12
凯雷Q4重仓押注StandardAero(SARO.US) 建仓中国自动驾驶公司文远知行(WRD.US)、小马智行(PONY.US)
根据美国证券交易委员会(SEC)披露，全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2024年12月31日的第四季度持仓报告(13...
02-14 17:12
Cantor Fitzgerald Reiterates Overweight on Soleno Therapeutics, Maintains $67 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and maintains $67 price target.
2024-09-21 00:28
HC Wainwright & Co. Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces Price Target of $70
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and announces Price Target of $70.
2024-09-03 19:49
HC Wainwright Initiates Soleno Therapeutics at Buy
06:28 AM EDT, 09/03/2024 (MT Newswires) -- Soleno Therapeutics (SLNO) has an average buy rating and a price target range of $59 to $93, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia ...
2024-09-03 18:28
